肌肉生长抑制素:从生物学基础到临床应用。

2区 医学 Q1 Chemistry
Advances in Clinical Chemistry Pub Date : 2022-01-01 Epub Date: 2021-11-17 DOI:10.1016/bs.acc.2021.09.006
Pasquale Esposito, Daniela Picciotto, Yuri Battaglia, Francesca Costigliolo, Francesca Viazzi, Daniela Verzola
{"title":"肌肉生长抑制素:从生物学基础到临床应用。","authors":"Pasquale Esposito,&nbsp;Daniela Picciotto,&nbsp;Yuri Battaglia,&nbsp;Francesca Costigliolo,&nbsp;Francesca Viazzi,&nbsp;Daniela Verzola","doi":"10.1016/bs.acc.2021.09.006","DOIUrl":null,"url":null,"abstract":"<p><p>Myostatin is a member of the transforming growth factor (TGF)-β superfamily. It is expressed by animal and human skeletal muscle cells where it limits muscle growth and promotes protein breakdown. Its effects are influenced by complex mechanisms including transcriptional and epigenetic regulation and modulation by extracellular binding proteins. Due to its actions in promoting muscle atrophy and cachexia, myostatin has been investigated as a promising therapeutic target to counteract muscle mass loss in experimental models and patients affected by different muscle-wasting conditions. Moreover, growing evidence indicates that myostatin, beyond to regulate skeletal muscle growth, may have a role in many physiologic and pathologic processes, such as obesity, insulin resistance, cardiovascular and chronic kidney disease. In this chapter, we review myostatin biology, including intracellular and extracellular regulatory pathways, and the role of myostatin in modulating physiologic processes, such as muscle growth and aging. Moreover, we discuss the most relevant experimental and clinical evidence supporting the extra-muscle effects of myostatin. Finally, we consider the main strategies developed and tested to inhibit myostatin in clinical trials and discuss the limits and future perspectives of the research on myostatin.</p>","PeriodicalId":50872,"journal":{"name":"Advances in Clinical Chemistry","volume":"106 ","pages":"181-234"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"13","resultStr":"{\"title\":\"Myostatin: Basic biology to clinical application.\",\"authors\":\"Pasquale Esposito,&nbsp;Daniela Picciotto,&nbsp;Yuri Battaglia,&nbsp;Francesca Costigliolo,&nbsp;Francesca Viazzi,&nbsp;Daniela Verzola\",\"doi\":\"10.1016/bs.acc.2021.09.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Myostatin is a member of the transforming growth factor (TGF)-β superfamily. It is expressed by animal and human skeletal muscle cells where it limits muscle growth and promotes protein breakdown. Its effects are influenced by complex mechanisms including transcriptional and epigenetic regulation and modulation by extracellular binding proteins. Due to its actions in promoting muscle atrophy and cachexia, myostatin has been investigated as a promising therapeutic target to counteract muscle mass loss in experimental models and patients affected by different muscle-wasting conditions. Moreover, growing evidence indicates that myostatin, beyond to regulate skeletal muscle growth, may have a role in many physiologic and pathologic processes, such as obesity, insulin resistance, cardiovascular and chronic kidney disease. In this chapter, we review myostatin biology, including intracellular and extracellular regulatory pathways, and the role of myostatin in modulating physiologic processes, such as muscle growth and aging. Moreover, we discuss the most relevant experimental and clinical evidence supporting the extra-muscle effects of myostatin. Finally, we consider the main strategies developed and tested to inhibit myostatin in clinical trials and discuss the limits and future perspectives of the research on myostatin.</p>\",\"PeriodicalId\":50872,\"journal\":{\"name\":\"Advances in Clinical Chemistry\",\"volume\":\"106 \",\"pages\":\"181-234\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Clinical Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.acc.2021.09.006\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/11/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Chemistry\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.acc.2021.09.006","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/11/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Chemistry","Score":null,"Total":0}
引用次数: 13

摘要

肌生长抑制素是转化生长因子(TGF)-β超家族的一员。它在动物和人类骨骼肌细胞中表达,在那里它限制肌肉生长并促进蛋白质分解。其作用受到复杂机制的影响,包括转录和表观遗传调控以及细胞外结合蛋白的调节。由于其促进肌肉萎缩和恶病质的作用,肌生长抑制素已被研究为一种有希望的治疗靶点,以抵消肌肉质量损失的实验模型和不同肌肉萎缩情况的患者。此外,越来越多的证据表明,肌生长抑制素除了调节骨骼肌生长外,还可能在许多生理和病理过程中发挥作用,如肥胖、胰岛素抵抗、心血管疾病和慢性肾脏疾病。在本章中,我们回顾了肌肉生长抑制素生物学,包括细胞内和细胞外调节途径,以及肌肉生长抑制素在调节生理过程中的作用,如肌肉生长和衰老。此外,我们讨论了最相关的实验和临床证据,支持肌肉生长抑制素的肌肉外作用。最后,我们考虑了在临床试验中开发和测试的抑制肌肉生长抑制素的主要策略,并讨论了肌肉生长抑制素研究的局限性和未来前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Myostatin: Basic biology to clinical application.

Myostatin is a member of the transforming growth factor (TGF)-β superfamily. It is expressed by animal and human skeletal muscle cells where it limits muscle growth and promotes protein breakdown. Its effects are influenced by complex mechanisms including transcriptional and epigenetic regulation and modulation by extracellular binding proteins. Due to its actions in promoting muscle atrophy and cachexia, myostatin has been investigated as a promising therapeutic target to counteract muscle mass loss in experimental models and patients affected by different muscle-wasting conditions. Moreover, growing evidence indicates that myostatin, beyond to regulate skeletal muscle growth, may have a role in many physiologic and pathologic processes, such as obesity, insulin resistance, cardiovascular and chronic kidney disease. In this chapter, we review myostatin biology, including intracellular and extracellular regulatory pathways, and the role of myostatin in modulating physiologic processes, such as muscle growth and aging. Moreover, we discuss the most relevant experimental and clinical evidence supporting the extra-muscle effects of myostatin. Finally, we consider the main strategies developed and tested to inhibit myostatin in clinical trials and discuss the limits and future perspectives of the research on myostatin.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in Clinical Chemistry
Advances in Clinical Chemistry 医学-医学实验技术
CiteScore
10.60
自引率
0.00%
发文量
53
审稿时长
>12 weeks
期刊介绍: Advances in Clinical Chemistry volumes contain material by leading experts in academia and clinical laboratory science. The reviews cover a wide variety of clinical chemistry disciplines including clinical biomarker exploration, cutting edge microarray technology, proteomics and genomics. It is an indispensable resource and practical guide for practitioners of clinical chemistry, molecular diagnostics, pathology, and clinical laboratory sciences in general.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信